PMID- 38090528
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231213
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 12
IP  - 11
DP  - 2023 Nov 30
TI  - The landscape of immune therapy in vulnerable patients with advanced non-small 
      cell lung cancer: a narrative review.
PG  - 2310-2321
LID - 10.21037/tlcr-23-581 [doi]
AB  - BACKGROUND AND OBJECTIVE: The clinical development of immune checkpoint 
      inhibitors (ICIs) has led to substantial advances in the treatment of lung 
      cancer. In particular, the contribution of ICIs to the long-term survival of 
      certain patients with non-small cell lung cancer (NSCLC) has been reported. With 
      the accumulated experience in the use of ICIs, numerous studies have documented 
      the efficacy and safety of ICIs in patients with diverse backgrounds, including 
      those with problematic indications for drug therapy. In the current review, we 
      summarize the most recent literature-based findings on ICI administration in 
      vulnerable patients with NSCLC and provide an overview of the current status and 
      prospects of ICIs. METHODS: Herein, we defined vulnerable as the group of 
      patients with NSCLC and performance status (PS) >/=2 (poor PS), advanced age (>/=75 
      years), or cancer cachexia. We conducted a narrative review of the literature on 
      the efficacy and safety of ICIs in vulnerable patients with advanced NSCLC. KEY 
      CONTENT AND FINDINGS: Among the vulnerable patient group, poor PS was a strong, 
      poor prognostic factor, even in patients undergoing ICI therapy. ICI therapy in 
      older patients can be effective, although adverse events (AEs) should be 
      carefully monitored. The efficacy of ICI therapy in patients with cancer cachexia 
      is poor, with further therapeutic development warranted. CONCLUSIONS: Although 
      prior studies have evaluated lung cancer pharmacotherapy in various vulnerable 
      populations, clinical studies on the application of ICIs in patients with 
      vulnerable NSCLC are lacking in both number and quality. Further development of 
      these therapeutic agents, with the emergence of additional evidence regarding 
      their appropriate use in this population, is expected.
CI  - 2023 Translational Lung Cancer Research. All rights reserved.
FAU - Morimoto, Kenji
AU  - Morimoto K
AD  - Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, Kyoto, Japan.
FAU - Yamada, Tadaaki
AU  - Yamada T
AD  - Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, Kyoto, Japan.
FAU - Takayama, Koichi
AU  - Takayama K
AD  - Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231121
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC10713257
OTO - NOTNLM
OT  - Age
OT  - cancer cachexia
OT  - immune checkpoint inhibitor (ICI)
OT  - non-small cell lung cancer (NSCLC)
OT  - poor performance status (poor PS)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-581/coif). T.Y. serves 
      as an unpaid editorial board member of Translational Lung Cancer Research from 
      October 2021 to September 2023. T.Y. received grants from Pfizer, Ono 
      Pharmaceutical, Janssen Pharmaceutical, AstraZeneca plc, and Takeda 
      Pharmaceutical and personal fees from Eli Lilly. K.T. received grants from Chugai 
      Pharmaceutical and Ono Pharmaceutical and personal fees from AstraZeneca, Chugai 
      Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. The 
      other author has no conflicts of interest to declare.
EDAT- 2023/12/13 18:42
MHDA- 2023/12/13 18:43
PMCR- 2023/11/30
CRDT- 2023/12/13 13:10
PHST- 2023/09/11 00:00 [received]
PHST- 2023/11/07 00:00 [accepted]
PHST- 2023/12/13 18:43 [medline]
PHST- 2023/12/13 18:42 [pubmed]
PHST- 2023/12/13 13:10 [entrez]
PHST- 2023/11/30 00:00 [pmc-release]
AID - tlcr-12-11-2310 [pii]
AID - 10.21037/tlcr-23-581 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2023 Nov 30;12(11):2310-2321. doi: 10.21037/tlcr-23-581. 
      Epub 2023 Nov 21.